Also available in Persian — نسخه فارسی EN فا
❓ Unknown

Semaglutide Linked to Significant Reduction in Asthma Attacks and COPD Flare-Ups

1w ago September 9, 2026 1 min read 📰 ScienceDaily
📋 Key Takeaway

A large real-world study found that semaglutide, the active ingredient in Ozempic and Wegovy, is linked to nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups. This research suggests potential respiratory benefits of GLP-1 drugs beyond their diabetes and obesity treatment. The findings could influence healthcare strategies in Iran, particularly in managing respiratory diseases.

🔍 Quick Context Guide
💡 Bottom Line: Semaglutide may offer unexpected respiratory benefits, potentially transforming treatment for asthma and COPD.

👥 Key Players

Researchers MENTIONED
Conductors of the study
"Their findings could influence treatment protocols for respiratory diseases in Iran."
Healthcare Providers MENTIONED
Medical professionals in Iran
"They will need to consider these findings in managing patients with asthma and COPD."

📰 What Happened

A large real-world study found that semaglutide, an active ingredient in Ozempic and Wegovy, is linked to significant reductions in asthma attacks and COPD flare-ups. This suggests potential additional benefits of GLP-1 drugs beyond their established use for diabetes and obesity.

  • Semaglutide linked to nearly 40% fewer asthma attacks.
  • Associated with about 20% fewer COPD flare-ups.

💡 Why It Matters

🇮🇷 For Iran: This could lead to new treatment options for respiratory diseases, which are significant health issues in Iran.
🌍 Regional: Improved management of respiratory diseases could enhance public health outcomes in the region.
🌐 International: If confirmed, these findings could influence global healthcare practices and drug approvals.

📚 Background

Semaglutide is primarily known for its role in treating diabetes and obesity, but emerging research suggests it may also benefit respiratory health. Asthma and COPD are prevalent conditions that significantly impact quality of life.

GLP-1 receptor agonists Respiratory diseases
📡 Source: NEUTRAL
📊 Confidence: 70%
The findings are based on a real-world study, which typically provides valuable insights but requires further clinical trials for validation.

Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. It was also associated with about 20% fewer COPD flare-ups. Researchers say GLP-1 drugs may offer respiratory benefits in addition to their effects on diabetes and obesity, but clinical trials are needed to confirm the findings.

🏷️ Entities Mentioned

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →